1-溴-4-(4-溴丁氧基)丁烷 | 7239-41-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-溴-4-(4-溴丁氧基)丁烷
• 英文名称: 4,4'-Dibrom-dibutylether
• 英文别名: 1-Bromo-4-(4-bromobutoxy)butane
• CAS: 7239-41-0
• 化学式: C₈H₁₆Br₂O
• 分子量: 288.022
• InChiKey: YMNORPXRNJKRRR-UHFFFAOYSA-N

物化性质

• 沸点：
  97.0-97.6 °C(Press: 1 Torr)
• 密度：
  1.520 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-溴-4-(4-溴丁氧基)丁烷 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 以97%的产率得到1-Azido-4-(4-azidobutoxy)butane
  参考文献：
  名称：

  Size-Specific Ligands for RNA Hairpin Loops

  摘要：

  The targeting of one mRNA in the transcriptome requires small molecules that bind with substantial affinity and specificity. As such, compounds with specificity for individual RNA secondary structural motifs could be useful for targeting RNA. Described herein is the synthesis of a combinatorial library of 105 dimers of deoxystreptamine and the subsequent identification of compounds with specificity for specific RNA hairpin loop sizes, including tetraloops and octaloops. Such compounds will be useful for the perturbation of RNA function in vivo.

  DOI：

  10.1021/ja051685b
• 作为产物：
  描述：

  4,4'-氧基双(丁-1-醇) 在 吡啶 、 三溴化磷 作用下， 生成 1-溴-4-(4-溴丁氧基)丁烷
  参考文献：
  名称：

  Rethinking the Analysis of Ethnic Residential Patterns: Segregation, Isolation, or Concentration Thresholds in Auckland, New Zealand?

  摘要：

  Data from the 1996 New Zealand Census on ethnicity in Auckland Urban Area are used to illustrate a new approach to measuring spatial separation. The traditionally employed single‐number indices are found wanting and a method based on thresholds is introduced. This provides more detailed information on the geography of ethnic groups that is consistent with the requirements for testing hypotheses regarding the relationship between social and spatial distance. The results show that (with a few exceptions) Polynesian groups were more encapsulated groups in Auckland than were Asian and European groups, and that most of the European groups—along with the “host society,” the New Zealand Europeans—were not spatially exposed to members of the Polynesian and Asian groups.

  DOI：

  10.1111/j.1538-4632.2002.tb01087.x

文献信息

• Substituted (aryloxy)alkanoic acids as antagonists of slow-reacting substance of anaphylaxis
  作者：Ronald A. LeMahieu、Mathew Carson、Ru-Jen Han、William C. Nason、Margaret O'Donnell、Deborah L. Brown、Herman J. Crowley、Ann F. Welton

  DOI：10.1021/jm00384a029

  日期：1987.1

  chain to substituted (aryloxy)alkanoic acids was prepared. The compounds were evaluated for their ability to antagonize SRS-A-induced contractions of guinea pig ilea and LTE-induced bronchoconstriction in the guinea pig. The results showed that the compounds were all less potent than FPL-55712 in vitro, yet surprisingly, most were more potent by the inhalation route of administration. Some of the most

  制备了一系列化合物，其中标准SRS-A拮抗剂FPL-55712的4-乙酰基-3-羟基-2-丙基苯氧基部分通过多亚甲基或聚醚链与取代的（芳氧基）链烷酸相连。评价化合物拮抗SRS-A诱导的豚鼠回肠收缩和LTE诱导的豚鼠支气管收缩的能力。结果表明，这些化合物在体外均不如FPL-55712有效，但令人惊讶的是，大多数化合物在吸入途径下更有效。选择了一些最有效的类似物进行进一步的药理评估，与PAF或组胺相比，通过吸入，白三烯具有选择性拮抗作用。与FPL-55712相比，化合物28和37对LTE的效力更高（分别为40倍和80倍），
• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090233920A1

  公开（公告）日：2009-09-17

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。
• [EN] AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS<br/>[FR] DERIVES D'AZAINDOLYLPIPERIDINE COMME AGENTS ANTIHISTAMINIQUES ET ANTIALLERGIQUES
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2003082867A1

  公开（公告）日：2003-10-09

  This invention is directed to new potent and selective antagonists of H1 histamine receptors having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及新型H1组胺受体的高效选择性拮抗剂，其具有一般式(I)，以及它们的制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• Indolylpiperidine derivatives as antihistaminic and antiallergic agents
  申请人：——

  公开号：US20020147344A1

  公开（公告）日：2002-10-10

  1 Indolylpiperidine compounds of formula (I) wherein: A 1 represents an alkylene, alkyleneoxy, alkylenethio, alkanoyl or hydroxyalkylene group; A 2 represents a single bond, an alkylene or alkenylene group; W represents a single bond or a phenylene or furanylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; R 1 represents a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl alkoxy-alkoxyalkyl, phenylalkyl group wherein the phenyl ring is unsubstituted or substituted by one or more halogen atoms or alkyl, alkoxy or arylalkoxy groups, or a cycloalkylalkyl group wherein the cycloalkyl group is unsubstituted or substituted by one or more halogen atoms, alkyl groups or alkoxy groups; R 2 represents a hydrogen or halogen atom or an alkyl or alkoxy group; and R 3 represents a carboxyl group or a tetrazolyl group; and pharmaceutically acceptable salts thereof, process for their preparation and medicinal use.

  式（I）的吲哚哌啶化合物，其中： A1代表烷基、烷基氧基、烷基硫基、烷酰基或羟基烷基基团； A2代表单键、烷基或烯基基团； W代表单键或苯基或呋喃基团，该基团未取代或被一个或多个卤素原子、烷氧基团和/或烷基团取代； R1代表氢原子或烷基、烯基、炔基、烷氧基烷基、烯基氧基烷基、炔基氧基烷基、烷氧-烷氧基烷基、苯基烷基团，其中苯环未取代或被一个或多个卤素原子或烷基、烷氧或芳基氧基团取代，或环烷基烷基团，其中环烷基未取代或被一个或多个卤素原子、烷基或烷氧基取代； R2代表氢或卤素原子或烷基或烷氧基； R3代表羧基或四唑基团； 以及其药学上可接受的盐，其制备方法和药用。
• GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
  申请人：GEMPHIRE THERAPEUTICS INC.

  公开号：US20180297929A1

  公开（公告）日：2018-10-18

  This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

  这项发明提供了具有35μm至约90μm的PSD90的gemcabene药用可接受盐，用于纯化粗制gemcabene的方法，纯化后的gemcabene的药用可接受盐，gemcabene药用可接受盐���药物组合物，以及用于治疗和预防各种疾病的治疗和预防方法，包括脂质代谢异常。